{"id":5828,"date":"2024-02-20T18:17:57","date_gmt":"2024-02-20T09:17:57","guid":{"rendered":"https:\/\/hbio.jp\/news\/?p=5828"},"modified":"2024-02-20T18:17:58","modified_gmt":"2024-02-20T09:17:58","slug":"20240220-2","status":"publish","type":"post","link":"https:\/\/hbio.jp\/news\/en\/2024\/02\/20\/20240220-2\/","title":{"rendered":"“N-NOSE” Success in Identifying a New Cancer Type, Liver Cancer"},"content":{"rendered":"
\"\"<\/figure>\n\n\n\n

HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative Director: Takaaki Hirotsu; hereinafter referred to as “HIROTSU”) has successfully developed a cancer type specific test that can detect early stage liver cancer. \u201cN-NOSE plus\u201d has been added a new product lineup to the service and be starting today.<\/strong><\/p>\n\n\n\n

Cancer is now the leading cause of death among Japanese,\nand it is estimated that one in two Japanese will develop cancer during their\nlifetime. While early detection and early treatment are expected to improve the\ntreatment rate, the cancer screening uptake rate in Japan is not high. In order\nto change this situation, we have been conducting research and development to\ncreate a future in which cancer can be detected at an early stage by lowering\nthe hurdle to screening by developing a cancer test that is easy and affordable\nfor everyone to take.<\/p>\n\n\n\n

As a first step, in 2020, we succeeded in developing the\n“N-NOSE” nematode cancer test, which is a simple and inexpensive way\nto determine the risk of 15 types*1 of early-stage cancer throughout the body,\nas an unprecedented “gateway” to cancer testing. In 2022, we launched\nthe “N-NOSE plus Pancreas” service, the world’s first cancer-specific\ntest capable of detecting early-stage pancreatic cancer, which will play the\nnext role in early cancer detection. Now, liver cancer has been added to the\nN-NOSE plus service as the second phase.<\/p>\n\n\n\n

*1\u3000The cancer type cannot\nbe confirmed. For those who are determined to be at high risk, we recommend\nthat they consult a hospital immediately for early detection.<\/p>\n\n\n\n

\u25a0\u201dN-NOSE plus\u201d Service Details<\/strong>
\u201cN-NOSE plus” can be applied for by those who have received a high-risk grade (D or E) after taking the “N-NOSE” test. Using the urine submitted at the time of the “N-NOSE” test, the risk of pancreatic cancer and liver cancer is determined for each cancer type. There is no need to submit new urine.
Official service website : https:\/\/lp.n-nose.com\/<\/a><\/p>\n\n\n\n

\u201cN-NOSE\u201d Periodic Screening Plan \u00a513,800 : \u00a530,000
\u201cN-NOSE\u201d One-time Screening Plan \u00a514,800 : \u00a550,000 *<\/strong>
*Customers using the one-time inspection course until March 31, 2024 can also apply for the regular inspection course for the same price of \u00a530,000.<\/p>\n\n\n\n

Download PDF <\/a><\/a><\/div>","protected":false},"excerpt":{"rendered":"

HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative Director: Takaaki Hirotsu; hereinafte […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_locale":"en_US","_original_post":"5828","footnotes":""},"categories":[3],"tags":[],"class_list":["post-5828","post","type-post","status-publish","format-standard","hentry","category-press-release","en-US"],"acf":[],"_links":{"self":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/5828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/comments?post=5828"}],"version-history":[{"count":2,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/5828\/revisions"}],"predecessor-version":[{"id":5831,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/5828\/revisions\/5831"}],"wp:attachment":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/media?parent=5828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/categories?post=5828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/tags?post=5828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}